AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05761860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxytocin Nasal Spray
Description: Intranasal oxytocin placebo administration
Study NCT05761860 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Oxytocin Nasal Spray
Description: Intranasal oxytocin placebo administration
Study NCT05637840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: Collection of 36-84 urine samples over a 14 consecutive day period.
Study NCT05637840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
Study NCT04763902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE) Schedule
Description: \[See arm/group descriptions\]
Study NCT05964140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Study NCT05964140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Study NCT05218889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib + camrelizumab + nab-paclitaxel + S-1
Description: phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1
Study NCT05218889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel + gemcitabine
Description: nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
Study NCT06226246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROS VR CPR training program
Description: HEROS VR training program which combined video training and VR session
Study NCT06226246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional HEROS CPR training program
Description: Conventional HEROS training program using video learning
Study NCT05215587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEVAR
Description: A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
Study NCT05887765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
Study NCT05887765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,1mg/kg Dexamethasone
Description: administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
Study NCT06297590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3954068
Description: Administered IT
Study NCT06297590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IT
Study NCT06297590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
Study NCT06297590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
Study NCT06151964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
Study NCT06151964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching administration volumes for SC injection
Study NCT06536530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame-Based Training
Description: 40-50 min sessions, two sessions per week, for a total of eight weeks.
Study NCT06536530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Based Training
Description: 40-50 min sessions, two sessions per week, for a total of eight weeks.
Study NCT06536530 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-List
Description: Participants will not train with any program and they will not assist to any specific session or intervention
Study NCT05887765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,2mg/kg Dexamethasone
Description: administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
Study NCT06568432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP+SAA POCT
Description: CRP+SAA POCT will be provided in 20 village clinics in the intervention group
Study NCT06128109 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thioderm Strong
Description: Test Device
Study NCT06128109 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Juvéderm VOLUMA Lidocaine
Description: Comparator Device
Study NCT06536374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Tablets
Description: Trimethoprim 150mg is administered once daily for 3 months
Study NCT05983133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-EGFRd2
Description: Given into the vein (IV; intravenously)
Study NCT06454747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-030 gel 0.64%
Description: Topical application to face twice daily for 12 weeks.
Study NCT06454747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Topical application to face twice daily for 12 weeks.
Study NCT06454747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-030 gel 0.08%
Description: Topical application to face twice daily for 12 weeks.
Study NCT06265727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)
Study NCT06185764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-670
Description: Solution for intravenous administration.
Study NCT05528796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family.
Study NCT06185764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for intravenous administration.
Study NCT06649292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: SHR-A1904
Study NCT06649292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Docetaxel, Irinotecan
Description: Paclitaxel, Docetaxel, Irinotecan
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive enhanced usual care
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive enhanced usual care
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive ASCENT guide
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive ASCENT guide
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06198010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06198010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Attend video or phone calls with a CHW and/or PCM
Study NCT06198010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Pain Management
Description: Receive personalized pain management plan
Study NCT06462482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Study NCT06462482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Study NCT05374980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
Study NCT05374980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink a bottle of 200ml placebo every morning and evening for 8 weeks
Study NCT05742256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 1mg/kg
Description: Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
Study NCT05248373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus
Study NCT05248373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution with same composition as for vaccine formulation except rAds
Study NCT04988880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Expert Patient Program of Catalonia
Description: It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
Study NCT05458401 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: No drug will be administered during this study.
Study NCT05742256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 1.5mg/kg
Description: Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Study NCT05742256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Study NCT05188001 — intervention group
Intervention type: OTHER
Intervention: Not an Interventional Study
Description: Not an interventional Study
Study NCT04788550 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated toothpaste
Description: Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
Study NCT04788550 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluoride varnish (5% sodium fluoride)
Description: Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
Study NCT04788550 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CPP-ACP plus crème group
Description: Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
Study NCT04728321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104 lenvatinib
Description: Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
Study NCT04728321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 until disease progression or for a maximum of 24 months
Study NCT05725317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LID220365 contact lens
Description: Investigational delefilcon A spherical contact lens made with a modified manufacturing process
Study NCT05725317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LID006961 contact lens
Description: Commercially available delefilcon A spherical contact lens
Study NCT05945433 — intervention group
Intervention type: DEVICE
Intervention: anovo™ Surgical System
Description: The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
Study NCT05245344 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood withdrawal
Description: 25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
Study NCT05775614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroTainer®
Description: Clinical effect of preventive treatment - catheter flushing with UroTainer®
Study NCT05775614 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Clinical effect of preventive treatment - catheter flushing with saline solution
Study NCT04514458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
Description: Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Study NCT03674346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnoanalgesia group
Description: The running of a hypnosis session is protocolized and is based on three times:~* The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~* The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~* The time of return. It is time that allows the patient to regain his classic state of consciousness.
Study NCT03674346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meopa Group
Description: The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study.
Study NCT05646186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on microbiome analysis
Description: Personalized dietary intervention based on individual microbiome analysis
Study NCT05646186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-FODMAP diet
Description: Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
Study NCT06064227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention
Description: In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization.
Study NCT06179524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T-19 cell injection
Description: The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
Study NCT05238233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: One drop will be given to participants
Study NCT05238233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Pilocarpine
Description: One drop will be given to participants
Study NCT05238233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride
Description: One drop will be given to participants
Study NCT05238233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tono pen AVIA
Description: Participant intraocular pressures measured
Study NCT05238233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG4 Gonio
Description: Participant iridocorneal angle measured
Study NCT05238233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reichert phoropter
Description: Participant screened for hyperopia >+1 diopter
Study NCT06537219 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Assessment of pain severity,pain thresold of the fascia, pain sensitivity
Study NCT05322616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK07
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Study NCT05322616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Vehicle control
Study NCT05197894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
Study NCT05168696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality Glasses